| Valhalla Dental Associates | |
|
50 Legion Dr Valhalla NY 10595-2057 | |
| (914) 949-1323 | |
| (914) 421-0930 |
| Full Name | Valhalla Dental Associates |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 50 Legion Dr, Valhalla, New York |
| Authorized Official Name and Position | Paul Hilburg (OWNER) |
| Authorized Official Contact | 9149491323 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Valhalla Dental Associates 50 Legion Dr Valhalla NY 10595-2057 Ph: (914) 949-1323 | Valhalla Dental Associates 50 Legion Dr Valhalla NY 10595-2057 Ph: (914) 949-1323 |
| NPI Number | 1528383114 |
|---|---|
| Provider Enumeration Date | 04/07/2010 |
| Last Update Date | 04/07/2010 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528383114 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
Today, at the 52nd Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Philadelphia, a group of researchers from Stanford University will describe the latest developments toward their goal of integrating two existing medical devices - medical linear accelerators, or "linacs," which produce powerful X-rays for treating cancer, and magnetic resonance imagers (MRIs), which are widely used to image tumors in the human body.
Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.
Researchers from the UCLA School of Nursing examined clinical records and magnetic resonance imaging brain scans of patients who were recently diagnosed with sleep apnea, and discovered several apparent connections between thinning of the brain's cerebral cortex and apnea symptoms.
Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.
› Verified 9 days ago
Valhalla Dental Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 50 Legion Dr, Valhalla, NY 10595 Phone: 914-949-1323 Fax: 914-421-0930 | |
Valhalla Dental Associates, Llp Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 50 Legion Dr, Valhalla, NY 10595 Phone: 914-949-1323 Fax: 914-421-0930 | |
Westchester Oral And Maxillofacial Surgery, Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Grasslands Road, Westchester Medical Center, Valhalla, NY 10595 Phone: 973-535-1774 |